| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $146.1M | +43.7% |
| SG&A Expense | $134.6M | +87.4% |
| Operating Income | -$280.7M | -61.8% |
| Net Income | -$277.4M | -59.5% |
| EPS (Basic) | -$5.21 | -45.1% |
| EPS (Diluted) | -$5.21 | -45.1% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $67.5M | -35.1% |
| Short-term Investments | $524.7M | +94.7% |
| Current Assets | $599.8M | +56.6% |
| Total Assets | $630.2M | +39.3% |
| Current Liabilities | $51.0M | +70.3% |
| Total Liabilities | $72.0M | +139.4% |
| Stockholders' Equity | $558.2M | +32.1% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$161.6M | -26.3% |
| Capital Expenditures | $10.2M | +405.8% |
| Investing Cash Flow | -$215.6M | -357.9% |
| Financing Cash Flow | $340.7M | — |
| Free Cash Flow | -$171.8M | -32.2% |